Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Tarsus Pharmaceuticals, Inc.

Tarsus (NASDAQ:TARS) is a biopharmaceutical company that applies proven science and new technology to revolutionize treatment for patients, starting with eye care.

Armentum Partners

Horowitz Group

Vivo Capital

Aperture Venture Partners

Visionary Venture Fund

Flying L Partners

Frazier Healthcare Partners

The first and only FDA-approved treatment for Demodex blepharitis (DB) is now available! We’re delighted to introduce this new therapeutic to the eye care community and thrilled at its potential to help many patients living with this disease.

We are so appreciative of our superstar Tarsus team and the many partners who worked diligently to make this important milestone happen. 

Read the full press release here: https://lnkd.in/eEQW3SEv

🌺 Aloha from the Hawaiian Eye & Retina 2024 Meeting! 

We love kicking off the New Year by attending this important and engaging meeting! This year, we had the privilege of connecting with leading experts in eye care across a variety of different platforms to share experiences about Demodex blepharitis and eyelid health. We appreciate the unique perspectives and compelling discussion and look forward to continuing the dialogue as we move further into 2024. 

Today, we commemorate the incredible life and impact of Dr. Martin Luther King Jr.

His unwavering dedication to justice, equality, and unity continues to inspire us. Dr. King had a vision for a brighter, more inclusive future, and we strive to honor that vision in everything we do at Tarsus.

This #MLKDay, we encourage our Tarsans to volunteer in their communities and reflect on Dr. King's commitments to peace, service, and education.

The Tarsus crew celebrated the holidays and rang in the New Year traveling, relaxing and spending time with loved ones!

We prioritize the health and well-being of our Tarsans and look forward to this important recharge break at the end of each year. Swipe through to see some highlights of our winter wellness week.

Discover more about the values that shape our culture: https://lnkd.in/eGeFU8_E

As we bid farewell to 2023, we’d like to reflect on what an incredible year it’s been.

2023 was a milestone year – we received FDA approval for the first and only treatment for Demodex blepharitis and just a few weeks into launch, we are well on our way to helping millions of potential patients. We experienced tremendous growth as an organization, more than doubling in size, and we were recognized by numerous independent companies as a great place to work.

We are grateful to our investigators, eye care provider partners, patients and our passionate team of Tarsans who helped us get to where we are today.

We are inspired and motivated to start 2024 and continue to deliver on our vision to make a meaningful difference in eye care and to the patients we serve. We wish everyone a happy and healthy holiday season.

See here for XDEMVY prescribing info: https://bit.ly/3Rrf4YB

	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
net income	-1.32M -	-4.67M 254.06%	-26.81M 474.11%	-13.83M 48.43%	-62.09M 349.06%	-135.89M 118.86%
depreciation and amortization	1K -	37K 3,600%	96K 159.46%	312K 225%	325K 4.17%	877K 169.85%
deferred income tax		331K -	15K 95.47%	1.65M 10,873.33%		6.49M -
stock based compensation	9K -	18K 100%	839K 4,561.11%	8.46M 907.75%	13.46M 59.20%	19.83M 47.33%
change in working capital	126K -	485K 284.92%	1.46M 200.62%	1.37M 5.90%	-951K 169.31%	306K 132.18%
accounts receivables		-32K -	16K 150%	-73K 556.25%	-3.49M 4,680.82%	-14.13M 304.90%
inventory		32K -	-16K 150%	73K 556.25%	3.49M 4,680.82%	-3.11M 189.03%
accounts payables	131K -	245K 87.02%	3.24M 1,222.45%	3.88M 19.75%	821K 78.84%	13.24M 1,512.67%
other working capital	-5K -	240K 4,900%	-1.78M 842.50%	-2.51M 40.74%	-1.77M 29.35%	4.30M 342.89%
other non cash items		126K -	3.27M 2,491.27%	5.79M 77.34%	227K 96.08%	-9.10M 4,109.25%
net cash provided by operating activities	-1.18M -	-3.67M 210.48%	-21.14M 475.50%	3.75M 117.73%	-49.03M 1,408.16%	-117.49M 139.63%
investments in property plant and equipment	-7K -	-175K 2,400%	-456K 160.57%	-586K 28.51%	-506K 13.65%	-5.50M 987.35%
acquisitions net					144.12M -	4M 97.22%
purchases of investments					-149.44M -	-28.66M 80.82%
sales maturities of investments					5.32M -	174.77M 3,188.24%
other investing activites					-144.12M -	-4M 97.22%
net cash used for investing activites	-7K -	-175K 2,400%	-456K 160.57%	-586K 28.51%	-144.63M 24,580.72%	140.60M 197.22%
debt repayment		-1.99M -			-19.13M -	-10M 47.71%
common stock issued		57.46M -	91.67M 59.55%	5.49M 94.01%	74.35M 1,253.33%	120.18M 61.63%
common stock repurchased			-28K -
dividends paid
other financing activites	3.56M -	3.98M 11.62%	40.13M 908.70%	-5.47M 113.64%	38.76M 808.20%	20.00M 48.40%
net cash used provided by financing activities	3.56M -	59.45M 1,567.93%	131.77M 121.67%	21K 99.98%	93.99M 447,457.14%	130.18M 38.50%
effect of forex changes on cash						1 -
net change in cash	2.37M -	55.60M 2,241.91%	110.18M 98.17%	3.18M 97.11%	-99.67M 3,231.39%	153.29M 253.79%
cash at beginning of period	1K -	2.38M 237,400%	57.97M 2,340.93%	168.15M 190.05%	171.33M 1.89%	71.66M 58.17%
cash at end of period	2.38M -	57.97M 2,340.93%	168.15M 190.05%	171.33M 1.89%	71.66M 58.17%	224.95M 213.91%
operating cash flow	-1.18M -	-3.67M 210.48%	-21.14M 475.50%	3.75M 117.73%	-49.03M 1,408.16%	-117.49M 139.63%
capital expenditure	-7K -	-175K 2,400%	-456K 160.57%	-586K 28.51%	-506K 13.65%	-5.50M 987.35%
free cash flow	-1.19M -	-3.85M 223.36%	-21.59M 461.17%	3.16M 114.64%	-49.54M 1,666.60%	-123.00M 148.29%

COM:TARSUSRX

Tarsus Pharmaceuticals, Inc.

Last Close

46.40

22/11 21:00

Market Cap

1.07B

Beta: -

Volume Today

589.21K

Avg: -

Preview